


**Product Name** : MC180295  
**Cat. No.** : PC-35808  
**CAS No.** : 2237942-08-2  
**Molecular Formula** : C<sub>17</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub>S  
**Molecular Weight** : 358.416  
**Target** : Cyclin-dependent Kinase (CDK)  
**Solubility** : 10 mM in DMSO



## Biological Activity

MC180295 (MC-180295, MC 180295) is a novel potent, highly selective **CDK9** inhibitor with IC<sub>50</sub> of 5 nM, displays >22-fold selectivity over other CDKs.

MC180295 also shows high selectivity against a panel of 250 kinases at 1 μM.

MC180295 specifically inhibits the phosphorylation levels of Ser2 (pSer2); CDK9-mediated phosphorylation of BRG1 prevents it from being recruited to heterochromatin loci, while CDK9 inhibition allows BRG1 to remodel chromatin and alter gene expression.

MC180295 demonstrates broad anti-cancer activity in vitro and is effective in in vivo cancer models.

MC180295 also sensitizes to anti-PD1 in vivo, increases the numbers of CD45+ immune cells and the percentages of CD3+ T cells and activates dendritic cells in the tumor environment, while not kill human T lymphocytes and did not affect the ratio of CD4 and CD8 T cells in vivo.

## References

Zhang H, et al. *Cell*. 2018 Nov 15;175(5):1244-1258.e26.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com